Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Singer

Showing results (731-740 of 771) with videos related to

Pageof 78
Sort By:
Journal of the American Heart Association|October 20, 2021
Re-CHARGE-AF: Recalibration of the CHARGE-AF Model for Atrial Fibrillation Risk Prediction in Patients With Acute StrokeJeffrey M Ashburner, Xin Wang, Xinye Li, et al.
Journal of the American Heart Association|April 27, 2019
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF RegistryAlexander C Perino, Peter Shrader, Mintu P Turakhia, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Clinical Cardiology|August 19, 2023
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registriesToon Wei Lim, Alan John Camm, Saverio Virdone, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
Journal of Proteome Research|October 27, 2012
High-throughput isolation and characterization of untagged membrane protein complexes: outer membrane complexes of Desulfovibrio vulgarisPeter J Walian, Simon Allen, Maxim Shatsky, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Pageof 78

Showing results (731-740 of 771) with videos related to

Sort By:
Pageof 78
Journal of the American Heart Association|October 20, 2021
Re-CHARGE-AF: Recalibration of the CHARGE-AF Model for Atrial Fibrillation Risk Prediction in Patients With Acute StrokeJeffrey M Ashburner, Xin Wang, Xinye Li, et al.
Journal of the American Heart Association|April 27, 2019
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF RegistryAlexander C Perino, Peter Shrader, Mintu P Turakhia, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Clinical Cardiology|August 19, 2023
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registriesToon Wei Lim, Alan John Camm, Saverio Virdone, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
Journal of Proteome Research|October 27, 2012
High-throughput isolation and characterization of untagged membrane protein complexes: outer membrane complexes of Desulfovibrio vulgarisPeter J Walian, Simon Allen, Maxim Shatsky, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Pageof 78